title: A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe.
abstract: OBJECTIVE
  A pilot study to assess effectiveness of generic Nevirapine (NVP)+Zidovudine (AZT)+Lamivudine (3TC) as potent antiretroviral therapy (ART) in women exposed to either SD NVP or short course (SC) AZT through participation in prevention of mother-to-child transmission of HIV-1 (pMTCT) interventions, and their spouses.
  
  
  METHODS
  A pilot study of antiretroviral treatment of adults with AIDS.
  
  
  METHODS
  Primary health care clinics; Seke North and St Mary's in Chitungwiza, Zimbabwe.
  
  
  METHODS
  Women with pre-exposure to SD NVP or SC AZT and their spouses with CD4 count < 200 cells/
  
  
  METHODS
  Generic AZT/3TC twice daily plus NVP daily for the first 14 days and then twice a day thereafter, administered to the cohort.
  
  
  METHODS
  The baseline median CD4 count for women and men was 128.5 and 119.0 cells/ microL respectively. The geomean virus load was similar for the women and men. At weeks 16, 24 and 48, 82.8%, 85.1% and 73.8% had < 400 copies/ml of HIV RNA respectively. Only at 16 weeks, was the proportion of women (75.9%) with undetectable virus significantly lower than that for men (93.9%), p = 0.031. Median CD4 count for both men and women increased significantly, p < 0.001. There were no significant differences in virologic responses between the women with pre-exposure to SD NVP and SC AZT. The mean adherence for women and men was similar, > 98%.
  
  
  CONCLUSIONS
  Women showed a significantly reduced response top ART relative to men only at 16. However, prior exposure to SD NVP for PMTCT was no more likely to negatively influence responses to ART than use of SC AZT.
authors: Department of Immunology, College of Health Sciences, University of Zimbabwe, Mazoe Street, P O Box A 178, Avondale, Harare, Zimbabwe. lzijenah@healthnet.zw
authors: L S
authors: LS
authors: Zijenah
authors: G
authors: G
authors: Kadzirange
authors: S
authors: S
authors: Rusakaniko
authors: T
authors: T
authors: Kufa
authors: N
authors: N
authors: Gonah
authors: O
authors: O
authors: Tobaiwa
authors: C
authors: C
authors: Gwanzura
authors: E
authors: E
authors: Matsikire
authors: D A
authors: DA
authors: Katzenstein
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active; D016009:Chi-Square Distribution; D016568:Drugs, Generic / Q000008:administration & dosage; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008297:Male; D019829:Nevirapine / Q000008:administration & dosage*; D010865:Pilot Projects; D018454:Spouses; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D015215:Zidovudine / Q000008:administration & dosage*; D015030:Zimbabwe
chemical_list: D019380:Anti-HIV Agents; D016568:Drugs, Generic; D019259:Lamivudine; D015215:Zidovudine; D019829:Nevirapine